Medtronic today announced the launch of its Stedi extra support guidewire for use with its Evolut TAVR platform.
GALWAY, Ireland and CHICAGO, March 30, 2025 /PRNewswire/ — Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced late-breaking data on five-year outcomes from the Evolut ...
The companies agreed to enhance access to technology from DASI, a leader in AI-driven predictive modeling and digital twin ...
Nearly two years after the FDA opened up minimally invasive aortic heart valve replacements to younger, healthier people more likely to make it through open surgery with fewer complications, Medtronic ...
DUBLIN, March 27, 2024 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that the United States Food and Drug Administration (FDA) has approved the ...
A five-year study of Medtronic’s minimally invasive replacement heart valves showed safety results similar to open surgery, illustrating the long-term benefits of the procedure, which aims for shorter ...
The company launched its CoreValve Evolut Pro device in Europe for patients in the intermediate, high, and extreme risk category for open surgery. Amanda Pedersen Transcatheter aortic valve ...
The FDA has approved Medtronic plc’s Evolut FX TAVR system for patients with symptomatic severe aortic stenosis. During Medtronic’s fiscal first quarter earnings call CEO Geoffrey Martha said the ...
Medtronic plc reported data from a head-to-head trial backing its Evolut TAVR system against competitor Edwards Lifesciences Corp.’s Sapien platform, and the data showed particular promise of the ...
MedPage Today on MSN
First 7-Year Report of Low-Risk TAVR Reassures, With Finish Line Now in Sight
S AN FRANCISCO -- Long-term outcomes after transcatheter aortic valve replacement (TAVR) were looking more and more like ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback